BiotechTube
Home/Pipeline/Ignite 32‑Analyte RPPA Assay

Ignite 32‑Analyte RPPA Assay

Oncology

MarketActive

Key Facts

Indication
Oncology
Phase
Market
Status
Active
Company
Ignite Proteomics

About Ignite Proteomics

A proteomics platform delivering RPPA‑based biomarker assays for oncology decision support and pharma collaborations.

View full company profile

Therapeutic Areas

OncologyImmuno-oncology

Other Oncology Drugs

DrugCompanyPhase
Bi-XDC with PROTACsCoherent BiopharmaIND-enabling
Bi-XDC with RPTCoherent BiopharmaEarly-stage
mRNA Anticancer VaccineSunshine BiopharmaPreclinical Research
Biosimilar BevacizumabOrganon (2)Phase 3
Biosimilar PembrolizumabOrganon (2)Phase 3
BCL-2 Inhibitor ProgramVincerx PharmaPreclinical
Not specified in provided content3SbioVarious
Preclinical ProjectsZion PharmaPreclinical
Attenukine Oncology CandidateTevaPhase 1
XEMA Tumor Marker ELISA KitXEMA GroupCommercial
KRAS inhibitorRisen Pharma TechPreclinical/Phase 1
KEAP1 Activator ProgramVividion TherapeuticsPhase 1